Ascent Pharmaceuticals Inc FDA Inspection Record
Ascent Pharmaceuticals Inc is an FDA-registered facility (FEI 3009518416) located in Central Islip, NY, US. Registered operations: ANALYSIS; LABEL; MANUFACTURE; PACK. RegDataLab tracks 9 FDA inspections at this facility.
What FDA found at this site
- Latest inspection
- Aug 9, 2024: Voluntary Action Indicated (VAI)
- Inspections on record
- 9 (6 VAI, 3 NAI)
- Last OAI inspection
- None on record
- Warning letters
- None matched to this FEI. Many letters do not state an FEI: search warning letters by company name
- Recalls as the recalling firm
- 3, latest Nov 19, 2021
Inspections and what FDA cited
| Date | Result | What FDA cited |
|---|---|---|
| Aug 9, 2024 | Voluntary Action Indicated (VAI) | No citations listed |
| Sep 15, 2022 | Voluntary Action Indicated (VAI) | Failure to comply with REMS Implementation System (FDCA 505-1(f)(4)) |
| Oct 13, 2020 | Voluntary Action Indicated (VAI) | No citations listed |
| Nov 7, 2018 | No Action Indicated (NAI) | No citations listed |
| Jul 27, 2018 | No Action Indicated (NAI) | No citations listed |
| Feb 21, 2018 | No Action Indicated (NAI) | No citations listed |
| Nov 9, 2015 | Voluntary Action Indicated (VAI) | No citations listed |
| Sep 26, 2013 | Voluntary Action Indicated (VAI) | No citations listed |
| Dec 6, 2012 | Voluntary Action Indicated (VAI) | Following/documenting laboratory controls (21 CFR 211.160(a)) Washing and toilet facilities are deficient (21 CFR 211.52) Samples (various types) representative, identified properly (21 CFR 211.160(b)(1)) |
Recalls
| Date | Class | Recall | Product and reason |
|---|---|---|---|
| Nov 19, 2021 | Class II | D-0276-2022 | Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/325 mg, 100-count bottle, Rx… Product Mix-up |
| Oct 26, 2020 | Class II | D-0097-2021 | Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/325mg 100-count bottles, Rx… Presence of Foreign Tablet/Capsule: One bottle of Hydrocodone Bitartrate and Acetaminophen Tablets USP 10mg/325 mg contains one Losartan… |
| Jan 22, 2018 | Class III | D-0248-2018 | Oxycodone Hydrochloride Tablets, USP 15 mg, 100 count bottles, Rx only, Manufactured for… Labeling; Label Error Not Elsewhere Classified; label missing controlled substance CII symbol |
FDA record score
12 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. Each record below adds the points shown.
8 records behind this number
| Record | Date | Points x age weight | Adds |
|---|---|---|---|
| Inspection classified VAI | Aug 9, 2024 | 6 x 0.6 | 3.6 |
| Inspection classified VAI | Sep 15, 2022 | 6 x 0.6 | 3.6 |
| Class II recall D-0276-2022, this FEI as the recalling firm | Nov 19, 2021 | 4 x 0.6 | 2.4 |
| Inspection classified VAI | Oct 13, 2020 | 6 x 0.25 | 1.5 |
| Class II recall D-0097-2021, this FEI as the recalling firm | Oct 26, 2020 | 4 x 0.25 | 1 |
| Inspection classified VAI | Nov 9, 2015 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Sep 26, 2013 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Dec 6, 2012 | 10 years or older, so it adds no points | 0 |
When each source was last refreshed
| Records | Last refreshed | Source as of | Status |
|---|---|---|---|
| Inspections | Nov 17, 2026 | Newest record Nov 9, 2026 | Current |
| Inspection citations | Nov 17, 2026 | Newest record Nov 5, 2026 | Current |
| Compliance actions (warning letters, injunctions and other action types) | Nov 2, 2026 | Newest record Oct 29, 2026 | Current |
| Warning letter text | Nov 17, 2026 | Newest record Nov 10, 2026 | Current |
| Recalls (Enforcement Report) | Nov 17, 2026 | Newest record Nov 11, 2026 | Current |
| Form 483s and inspection documents | Nov 17, 2026 | Newest record Nov 16, 2026 | Current |
| Import refusals | Nov 15, 2026 | Newest record Nov 5, 2026 | Current |
Reviewing Ascent Pharmaceuticals Inc as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.
Or check Ascent Pharmaceuticals Inc yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.
Facility details
- Company
- Ascent Pharmaceuticals Inc
- Location
- Central Islip, NY (US)
- Registration Expires
- Dec 31, 2027
- Operations
- ANALYSIS; LABEL; MANUFACTURE; PACK
- Source
- decrs